Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

<< Previous

Bullboard Posts

Next >>

Post by ScienceFirston May 02, 2022 6:21pm

293 Views

Post# 34649352

Big pharmas are looking for a platform. We have one.

Given their size and resources, big pharmas are more looking for a platform, than just a molecule.

So lets see what we have:

- we now have one in oncology (with different indications advanced at different stages).
- we now have one in the making for the anti-virus market, with a credible partner (PHAC-NML).
- we have a PDC portfolio (TLD-1433, Rutherrin and other PDCs (Os, etc ...)) to be used by those platforms.

So a big pharma,

- can have the vision and has the resources to already take the steps to advance TLD-1433 in these others niches within the bladder cancer market.
- can decide to aim at 3-4 other oncology indications that TLD documented pre-clinically years ago (head & neck (Sept. 17, 2017), esophageal (Oct. 9, 2018), etc) with TLD-1433, Rutherrin and other PDCs (Os, etc ...).
- can become a Client of our Theralase Cancer Center that has, as an objective, to develop and commercialize PDCs to bring them to bedside and mainstream.

So big pharmas would pay to advance those new trial indications on many fronts, conditional to certain clinical trial milestones, just like Pfizer did it with BioNTech.

So now would be a perfect timing for them to step in.

I don't think a big Pharma would wait for Breakthrough designation in NMIBC to do a move. They now have enough data and they have enough expertise to assess our anti-cancer technology (ACT) now to easily propose a jv deal with milestones and trial result conditions.

That could explain the creation of the Theralase Research Center so our pipeline of PDCs can feed a big pharma's intentions. TLT would have done all the heavy lifting with the NMIBC indication (TLD-1433), NSCLC (preclinical with Rutherrin) and a proof-of-concept with the anti-virus platform (COVID-19) with PHAC-NML. That would legitimately set the table for a big pharma to step in a bit before the NMIBC Breakthrough designation and would target other indications not yet engaged by TLT (NMIBC, NSCLC, COVID-19) because big pharmas are competing one against each others, one has to move faster than the others if it wants to reap the big rewards.

PDT is DESTROYING tumors instantly, at speed of light. Just not shrinking tumors over many treatments.